Crossmark

Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study

Crossref DOI link: https://doi.org/10.1016/j.artere.2025.100724

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pallarés-Carratalá, Vicente https://orcid.org/0000-0002-2985-6078
Ruiz-García, Antonio https://orcid.org/0000-0002-7902-5504
Serrano-Cumplido, Adalberto https://orcid.org/0000-0001-7355-423X
Fragoso, Antonio Segura https://orcid.org/0000-0003-4884-2242
Fernández-Pascual, Verónica https://orcid.org/0009-0008-4371-1431
Sánchez-Sánchez, Beatriz https://orcid.org/0000-0002-9302-353X
Cervera-Pérez, María Inmaculada

Alonso-Moreno, Francisco Javier https://orcid.org/0000-0002-2886-3620
Arranz-Martínez, Ezequiel https://orcid.org/0000-0003-0456-3444
Barquilla-García, Alfonso https://orcid.org/0000-0001-7074-4951
Rey-Aldana, Daniel https://orcid.org/0000-0003-2929-8739
García, José Polo https://orcid.org/0000-0002-3655-7180
Cinza-Sanjurjo, Sergio https://orcid.org/0000-0002-4486-2820
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01
More Information

This article is maintained by: Elsevier

Article Title: Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study

Journal Title: Clínica e Investigación en Arteriosclerosis (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.artere.2025.100724

Content Type: article

Copyright: © 2025 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.

Document is current

Any future updates will be listed below